These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity. Ramírez MA; Loaiza RA; Martínez-Balboa Y; Bruneau N; Ramírez E; González PA; Bueno SM; Kalergis AM Vaccine; 2024 Oct; 42(23):126203. PubMed ID: 39178767 [TBL] [Abstract][Full Text] [Related]
4. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus. Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2. Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987 [TBL] [Abstract][Full Text] [Related]
6. A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan. He Y; Yu W; Shen L; Yan W; Xiao L; Qi J; Hu T Int J Biol Macromol; 2022 Dec; 222(Pt A):661-670. PubMed ID: 36152702 [TBL] [Abstract][Full Text] [Related]
8. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669 [TBL] [Abstract][Full Text] [Related]
9. Adjuvants to increase immunogenicity of SARS-CoV-2 RBD and support maternal-fetal transference of antibodies in mice. Lima GG; Portilho AI; De Gaspari E Pathog Dis; 2022 Oct; 80(1):. PubMed ID: 36220147 [TBL] [Abstract][Full Text] [Related]
10. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses. Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465 [TBL] [Abstract][Full Text] [Related]
12. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine. Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661 [TBL] [Abstract][Full Text] [Related]
13. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2. Dulin H; Barre RS; Xu D; Neal A; Vizcarra E; Chavez J; Ulu A; Yang M-S; Khan SR; Wuang K; Bhakta N; Chea C; Wilson EH; Martinez-Sobrido L; Hai R J Virol; 2024 Feb; 98(2):e0157123. PubMed ID: 38206036 [TBL] [Abstract][Full Text] [Related]
15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
16. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802 [TBL] [Abstract][Full Text] [Related]
17. RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. Phatarphekar A; Vidyadhar Reddy GEC; Gokhale A; Karanam G; Kuchroo P; Shinde K; Masand G; Pagare S; Khadpe N; Pai SS; Vijayan V; Ramnath RL; Pratap Reddy K; Rao P; Harinarayana Rao S; Ramana V Vaccine; 2022 Jul; 40(32):4522-4530. PubMed ID: 35718590 [TBL] [Abstract][Full Text] [Related]
18. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2. Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003 [TBL] [Abstract][Full Text] [Related]
19. Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant. Ji J; Tang T; Zhu M; Wu Z; Zhang J; Shi D; Zhu L; Zhang X; Lu X; Chen L; Yao H Antiviral Res; 2024 Sep; 229():105954. PubMed ID: 38964615 [TBL] [Abstract][Full Text] [Related]
20. [Preparation and immungenicity of recombinant protein containing intramolecular adjuvant in SARS-CoV-2 RBD domain]. Jiang J; Wang Y; Li Y; Wang J; Zhang Y; Wang X; Wang X; Zhang H Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3353-3362. PubMed ID: 36151805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]